Cargando…

Immunotherapy Outcomes in Individuals With Non–Small Cell Lung Cancer and Poor Performance Status

BACKGROUND: Patients with non–small cell lung cancer (NSCLC) treated in real-world practice typically have worse performance status (PS) compared with clinical trial patients, and the effectiveness of immunotherapy in this population in unknown. In this study, we assessed the effectiveness of standa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veluswamy, Rajwanth, Hu, Liangyuan, Smith, Cardinale, Ji, Jiayi, Wang, Xiaoliang, Wisnivesky, Juan, Morillo, Jose, Kale, Minal S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921740/ https://www.ncbi.nlm.nih.gov/pubmed/35603847 http://dx.doi.org/10.1093/jncics/pkac013

Ejemplares similares

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study
por: Leiter, Amanda, et al.
Publicado: (2022)

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States
por: Veluswamy, Rajwanth, et al.
Publicado: (2022)

Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality
por: Song, Xiaoyu, et al.
Publicado: (2021)

3363 Prognostic Value of Immune-Related Biomarkers in Resected Non-Small Cell Lung Cancer
por: Veluswamy, Rajwanth R, et al.
Publicado: (2019)

PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis
por: Tuminello, Stephanie, et al.
Publicado: (2020)

Estimation of causal effects of multiple treatments in observational studies with a binary outcome
por: Hu, Liangyuan, et al.
Publicado: (2020)

Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
por: Tuminello, Stephanie, et al.
Publicado: (2022)

Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis
por: Tuminello, Stephanie, et al.
Publicado: (2019)

Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities
por: Sigel, Keith, et al.
Publicado: (2021)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
por: Sun, Young JUNG, et al.
Publicado: (2011)

Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
por: Wisnivesky, Juan P., et al.
Publicado: (2021)

Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status
por: Aida, Yuka, et al.
Publicado: (2019)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

The Association of Health Literacy with Illness and Medication Beliefs among Patients with Chronic Obstructive Pulmonary Disease
por: Kale, Minal S., et al.
Publicado: (2015)

Machine learning to identify and understand key factors for provider-patient discussions about smoking
por: Hu, Liangyuan, et al.
Publicado: (2020)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
por: Katsura, Hideyuki, et al.
Publicado: (2019)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Identifying and assessing the impact of key neighborhood-level determinants on geographic variation in stroke: a machine learning and multilevel modeling approach
por: Ji, Jiayi, et al.
Publicado: (2020)

Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach
por: Hu, Liangyuan, et al.
Publicado: (2020)

Tree‐Based Machine Learning to Identify and Understand Major Determinants for Stroke at the Neighborhood Level
por: Hu, Liangyuan, et al.
Publicado: (2020)

A Flexible Approach for Assessing Heterogeneity of Causal Treatment Effects on Patient Survival Using Large Datasets with Clustered Observations
por: Hu, Liangyuan, et al.
Publicado: (2022)

High expression of DARS2 indicates poor prognosis in lung adenocarcinoma
por: Jiang, Yingfeng, et al.
Publicado: (2022)

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer
por: Abbas, M. Nazim, et al.
Publicado: (2021)

Association of Vaccination with the Persistence of Post-COVID Symptoms
por: Wisnivesky, Juan P., et al.
Publicado: (2022)

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
por: Cho, Ju Hwan
Publicado: (2017)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)

Radiotherapy for glioblastoma patients with poor performance status
por: Schröder, Christina, et al.
Publicado: (2021)

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
por: Banna, Giuseppe L., et al.
Publicado: (2021)

Chemotherapy in geriatric patients with poor performance status small cell lung cancer: Series from a tertiary care center
por: Sundriyal, Deepak, et al.
Publicado: (2022)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

A flexible approach for causal inference with multiple treatments and clustered survival outcomes
por: Hu, Liangyuan, et al.
Publicado: (2022)

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study
por: Wisnivesky, Juan P, et al.
Publicado: (2011)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
por: Wei, Zhong, et al.
Publicado: (2008)

Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
por: Lee, Keun-Wook, et al.
Publicado: (2008)

Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
por: Karim, Nagla Abdel, et al.
Publicado: (2014)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prdancnk06talkfhfcu10cfo5a